SCHEMBL10042341

SCHEMBL10042341

COc1cc(C(O)C(N)C(=O)O)ccc1C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.78
BLM P54132 2/20 0.54
NR1I2 O75469 1/20 0.54
PTGS1 P23219 1/20 0.54
ADRA1A P35348 1/20 0.54
LMNA P02545 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
NPSR1 Q6W5P4 1/20 0.48
TSHR P16473 1/20 0.48
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
AKR1C3 P42330 3/20 0.41
AKR1C2 P52895 3/20 0.41
TUBB4A P04350 2/20 0.40
TUBB P07437 2/20 0.40
TUBA3C P0DPH7 2/20 0.40
TUBA1B P68363 2/20 0.40
TUBA4A P68366 2/20 0.40
TUBB4B P68371 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7428417 0.88 ACHE (1.00) ACHEBLMNR1I2PTGS1ADRA1A
SCHEMBL7427390 0.88 ACHE (1.00) ACHEBLMNR1I2PTGS1ADRA1A
SCHEMBL7611352 0.85 ACHE (0.78) ACHEBLMNR1I2PTGS1ADRA1A
Acetic Acid SCHEMBL7438982 0.85 ACHE (0.94) ACHEBLMNR1I2PTGS1ADRA1A
SCHEMBL4092902 0.85 ACHE (0.78) ACHEBLMNR1I2PTGS1ADRA1A
SCHEMBL804060 0.81 BLM (0.71) ACHEBLMLMNANPSR1TSHR
SCHEMBL18857450 0.80 ACHE (0.79) ACHEBLMNR1I2PTGS1ADRA1A
SCHEMBL3677141 0.78 AKR1C3 (0.62) ACHEBLMPTGS1NPSR1TSHR
SCHEMBL16865533 0.78 AKR1C3 (0.62) ACHEBLMPTGS1NPSR1TSHR
SCHEMBL16865529 0.78 AKR1C3 (0.62) ACHEBLMPTGS1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266817-B2 Catecholamine derivatives for obesity and neurological disorders EMORY UNIVERSITY (US) 2016-02-23 US disclosed
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-11-06 US disclosed
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS EMORY UNIVERSITY (US) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT ACHE 280/4885BLM 4562/4885NR1I2 2405/4885
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT ACHE 280/4885BLM 4562/4885NR1I2 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.